Other Events ·
Atrium Therapeutics, Inc. announced on July 14, 2026, that the U.S. Food and Drug Administration has cleared its…
RNAAtrium Therapeutics, Inc.
Atrium Therapeutics, Inc. announced on July 14, 2026, that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with its Corventis™ Phase 1/2 clinical trial for treating Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. Atrium Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for genetic disorders.